If you’re looking to stay up to date with the latest commercialization news out of the Office of Research and Technology Management at ºÚÁϳԹÏÍø, you’ve come to the right place. Explore some of our latest headlines relating to inventions, startups and more from researchers at ºÚÁϳԹÏÍø.
2025
PR Newswire | March 11, 2025
Trailhead Biosystems | March 5, 2025
BusinessWire | Feb. 11, 2025
NervGen | Feb. 6, 2025
PR Newswire | Feb. 5, 2025
EU-Startups.com | Jan. 28, 2025
Crain’s Cleveland Business | Jan. 17, 2025
Energy.gov | Jan. 8, 2025
2024
University Hospitals | Dec. 17, 2024
Forbes | Dec. 11, 2024
Global NewsWire | Nov. 14, 2024
PR Newswire | Oct. 29, 2024
FreshWater | Oct. 24, 2024
NutraIngredients USA | Oct. 16, 2024
PR Newswire | Sept. 26, 2024
MetroHealth | Sept. 9, 2024
PR Newswire | Aug. 28, 2024
News 5 Cleveland | Aug. 22, 2024
University Hospitals | Aug. 9, 2024
The Daily | July 12, 2024
NervGen | June 25, 2024
WKYC | April 21, 2024
DefiniGEN | June 3, 2024
Crain’s Cleveland Business | March 18, 2024
PR Newswire | March 7, 2024
Crain’s Cleveland Business | Feb. 20, 2024
The Daily | Feb. 19, 2024
BusinessWire | Feb. 1, 2024
The Daily | Jan. 5, 2024
2023
Amgen.com | Nov. 28, 2023
Luciddx.com | Oct. 31, 2023
Nervgen.com | Oct. 23, 2023
Nervgen.com | Sept. 25, 2023
Bioinformant | Sept. 18, 2023
Cleveland.com | July 25, 2023
Crain's Cleveland Business | July 11, 2023
PAVmed | May 11, 2023
AUTM | April 21, 2023
PAVmed | April 18, 2023
NervGen | April 13, 2023
NervGen | March 30, 2023
NutraIngredients USA | March 16, 2023
Cleveland.com | March 15, 2023
The Daily | March 8, 2023
The Business Journal Daily | March 8, 2023
The Daily | Feb. 23, 2023
Crain's Cleveland Business | Feb. 23, 2023
PAVmed | Feb. 15, 2023
The Daily | Feb. 14, 2023
NervGen | Feb. 14, 2023
The Daily | Feb. 13, 2023
Fox 8 WJW | Feb. 7, 2023
Forbes | Jan. 27, 2023
The Plain Dealer | Jan. 26, 2023
Ideastream Public Media | Jan. 26, 2023
Drug Discovery and Development | Jan. 18, 2023
The Daily | Jan. 17, 2023
2022
Lucid Diagnostics | Dec. 8, 2022
The Daily | Dec. 8, 2022
Lucid Diagnostics | Dec. 1, 2022
Exclusive license agreement with ºÚÁϳԹÏÍø for Core-NK platform
Chimeric Therapeutics | Nov. 21, 2022
PAVmed | Dec. 1, 2022
PAVmed | Dec. 8, 2022
The Daily | Dec. 8, 2022
The Daily | Nov. 21, 2022
Ohio Department of Development | Oct. 18, 2022
NervGen | Oct. 25, 2022
The Daily | Sept. 14, 2022
The Daily | Sept. 8, 2022
The Daily | Sept. 8, 2022
The Daily | Sept. 9, 2022
Folio Photonics Announces Breakthrough Multi-Layer Optical Disc Storage Technology to Enable Industry-Disruptive Cost, Cybersecurity and Sustainability Benefits
Folio Photonics | Aug. 30, 2022
PAVmed | Aug. 11, 2022
NervGen | Aug. 10, 2022
Lucid Diagnostics | Aug. 4, 2022
BusinessWire | Aug. 3, 2022
NervGen | Aug. 2, 2022
PAVmed | Aug. 2, 2022
NervGen | July 14, 2022
RAD adds brain tumor technology to portfolio
Radiopharm Theranostics | June 9, 2022
The Daily | May 25, 2022
AccessWire | May 12, 2022
PAVmed | May 9, 2022
PAVmed | April 4, 2022
NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
NervGen | March 31, 2022
PAVmed | March 24, 2022
PAVmed | March 23, 2022
NervGen | March 15, 2022
PAVmed | March 3, 2022
The Daily | Feb. 11, 2022
The Daily | Jan. 27, 2022
News 5 Cleveland | Jan. 21, 2022
The Daily | Jan. 20, 2022
Crain's Cleveland Business | Jan. 20, 2022
Crain's Cleveland Business | Jan. 19, 2021
The Daily | Jan. 5, 2022
2021
NervGen | Dec. 22, 2021
The Daily | Dec. 22, 2021
PAVmed | Dec. 1, 2021
Global NewsWire | Nov. 30, 2021
NervGen Pharma Corp. Closes Non-Brokered Private Placement
NervGen | Nov. 29, 2021
First Point-of-Care Test for Serious Hemoglobin Disorder, Beta Thalassemia, Provides New Weapon for the Front Lines of Healthcare Worldwide
Hemex Health | Nov. 24, 2021
NervGen | Nov. 18, 2021
Lucid Diagnostics | Nov. 11, 2021
NervGen | Nov. 4, 2021
Lucid Diagnostics | Oct. 28, 2021
The Daily | Oct. 20, 2021
NervGen | Oct. 18, 2021
PAVmed | Oct. 13, 2021
Crain's Cleveland Business | Oct. 8, 2021
NervGen Pharma | Sept. 27, 2021
Crain's Cleveland Business | Sept. 24, 2021
PAVmed | Sept. 23, 2021
Fierce Biotech | Sept. 23, 2021
PAVmed: A Small Cap Puts Its Streamlined Development Model to the Test
MyStrategist.com/MedTech-Strategist | Aug. 19, 2021
Business Wire | Aug. 10, 2021
Business Insider | Aug. 9, 2021
MedTech Strategist | Aug. 2, 2021
PRNewswire | July 22, 2021
AUTM | July 16, 2021
Neuros Medical | June 29, 2021
BusinessWire | June 28, 2020
Stockhouse | June 28, 2021
TechOhio, June 24, 2021
The Daily | June 15, 2021
PAVmed | June 10, 2021
NervGen | June 10, 2021
MedLumics | May 28, 2021
PAVmed | May 26, 2021
NervGen | May 20, 2021
The Daily | May 7, 2021
NervGen | May 6, 2021
The Daily | May 5, 2021
The Daily | April 29, 2021
Diagnostic Imagining | April 25, 2021
NervGen Pharma | April 22, 2021
Eurek Alert | April 22, 2021
Crain's Cleveland Business | April 20, 2021
FreshWater Cleveland | April 22, 2021
Business Wire | April 13, 2021
The Daily | April 8, 2021
The Daily | March 31, 2021
PRNewswire | March 30, 2021
The PharmaLetter | March 30, 2021
Equalize | Feb. 18, 2021
NervGen | March 8, 2021
NervGen | March 2, 2021
PAVmed | Feb. 22, 2021
The Daily | Feb. 11, 2021
NervGen | Jan. 27, 2021
NervGen’s 2020 in Review and the Plan Ahead
NervGen | Jan. 11, 2021
Neuros Medical | Jan. 6, 2021
Neuros Medical | Jan. 6, 2021
Dravet Syndrome News | Jan. 5, 2021
NervGen Pharma | Jan. 5, 2021